LabCorp reported third-quarter revenue growth of 7%, margin expansion of 60 basis points and adjusted EPS growth of 14.5%, raising full-year revenue guidance by $65 million and adjusted EPS guidance by 18 cents.
LH · Labcorp Holdings Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Labcorp Holdings Inc. said Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10 at 8:45 a.m. ET.
Labcorp reported revenue of $3,810.0 million for the three months ended September 30, 2026, up 6.9% from $3,563.5. Revenue for the nine months reached $11,078.7 million, up 6.2%, while operating cash flow rose to $1,200.8 million.
LabCorp reported third-quarter revenue of $3.8 billion, up 6.9%, and adjusted EPS of $4.78, up 14.5%. It raised its full-year 2026 adjusted EPS guidance to $18.30 to $18.70.
Labcorp reported third-quarter 2026 revenue of $3.81 billion, up 6.9%, and adjusted EPS of $4.78, up 14.5%. It raised 2026 revenue growth guidance to 5.9% to 6.7% and adjusted EPS guidance to $18.30 to $18.70.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Oct 28, 2026TL;DR. Labcorp reported 6.9% revenue growth, 14.5% adjusted EPS growth and 60 basis points of adjusted operating-margin expansion, raised full-year guidance, and delivered growth and margin expansion in Diagnostics and Biopharma Laboratory Services amid acquisition and specialty-testing activity. PAMA is expected to create an approximately $125 million impact in 2027, while ACA was a 30-basis-point diagnostic-volume headwind, foreign currency’s benefit to guidance was lower than previously expected, and GAAP operating margin contracted 60 basis points.
- + Labcorp raised its full-year 2026 enterprise revenue growth guidance to 5.9%-6.7% and adjusted EPS guidance to $18.30-$18.70.
- + Labcorp announced or closed four transactions expected to be accretive to adjusted EPS in year one and to return cost of capital by year three.
- − The proposed PAMA payment cuts threaten patient access, patient care, innovation and laboratory viability.
- − ACA changes reduced third-quarter diagnostic volume by approximately 30 basis points, with a similar impact expected in the fourth quarter.
- − An approximately $10 million incremental foreign-currency headwind versus prior guidance constrained the otherwise stronger revenue outlook.
- − Third-quarter GAAP operating margin contracted 60 basis points to 10.6%.
- − Planned capital-expenditure increases partially offset the year-over-year improvement in free cash flow.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| BLS segment operating margin | 17% | the three months ended June 30, 2026 filing | — |
| Dx segment operating margin | 18% | the three months ended June 30, 2026 filing | — |
| Adjusted EPS non-GAAP | $4.99 | Q2 2026 | — |
| Adjusted Operating Income non-GAAP | $1.1B | Six Months Ended June 30, 2026 | — |
| AOI as % of Revenue non-GAAP | 15.8% | Q2 2026 | — |
| Backlog | $8.73B | As of June 30, 2026 | — |
| Capital Expenditures | $131.6M | Q2 2026 | — |
| Free Cash Flow non-GAAP | $384.4M | Six Months Ended June 30, 2026 | — |
| Next Twelve Months Forecast Backlog Conversion | $2.75B | As of June 30, 2026 | — |
| Operating Cash Flow | $445.5M | Q2 2026 | — |
| TTM Book to Bill | 1.03 | As of June 30, 2026 | — |
| TTM Net Orders | $3.32B | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LH
this stock
Labcorp Holdings Inc.
|
$29.90B | +46.8% | +7.2% | 30.2 | 3.1% |
|
TMO
Thermo Fisher Scientific Inc.
|
$254.47B | +18.5% | +14.5% | 36.2 | 1.3% |
|
DHR
Danaher Corp
|
$158.84B | -1.4% | +8.5% | 36.9 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$54.38B | +2.0% | +10.4% | 46.5 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$48.55B | +26.6% | +6.4% | 33.9 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 35
LabCorp reported third-quarter revenue growth of 7%, margin expansion of 60 basis points and adjusted EPS growth of 14.5%, raising full-year revenue guidance by $65 million and adjusted EPS guidance by 18 cents.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LH | -0.7% | +14.0% | +40.2% | +1.9% | +46.8% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | +1.6% | +18.7% | +43.1% | +5.0% | +39.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.